AGIO

Agios Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth 1/10
  • Value 0/10
Agios Pharmaceuticals sales and earnings growth
AGIO Growth
Low
  • Revenue Y/Y 74.39%
  • EPS Y/Y -162.02%
  • FCF Y/Y 4.72%
Agios Pharmaceuticals gross and profit margin trends
AGIO Profitability
Neutral
  • Gross margin 90.00%
  • EPS margin -639.80%
  • ROIC 5Y -1.07%
Agios Pharmaceuticals net debt vs free cash flow
AGIO Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage NA

Agios Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks